Vertex Pharmaceuticals' Recuperation Will Continue, Vetr Crowd Says

Shares of Vertex Pharmaceuticals Incorporated VRTX have lost 28.5 percent of their value since the beginning of the year. However, the past month saw the stock gain 9.4 percent. It seems like the Vetr crowd believes the rally will continue, as suggested by its average price target of $94.50, which implies an upside potential of 6.1 percent from current valuations.

Related Link: Here's How Crowdsourced Ratings Can Beat The Market

Seeking to better reflect this upside potential, the Vetr community decided upgrade its rating on shares of Vertex on Thursday, from 3.0 Stars (Hold) to 3.5 Stars (Buy) - out of a possible 5.0 Stars rating.

Finally, it should be noted that, in accordance with the new rating, 72 percent of the crowd’s ratings are bullish.

Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.